ea0092ps2-16-07 | Thyroid Cancer clinical 2 | ETA2023
Trevisan Matteo
, De Leo Simone
, Vanessa Re Sarto Giulia
, Moneta Claudia
, Pirovano Marta
, Colombo Carla
, Cosmai Laura
, Fugazzola Laura
Selpercatinib is a specific RET inhibitor, highly effective in the treatment of advanced RET-mutant medullary thyroid carcinoma (MTC). The consequences of selpercatinib administration in MTC patients who have not undergone thyroid surgery are still unknown. We report the case of an 84-year-old man undergoing investigations for worsening diarrhea and weight loss. Upon a neck ultrasound scan and blood exams that pointed out high levels of both calcitonin (CT, 20.583 ng/l) and ca...